Brought to you by 
GSK options Nabi's nicotine addiction vaccine NicVAX; terminated
11 Dec 2015
Executive Summary
After teaming up earlier this year, GlaxoSmithKline Biologicals SA and Nabi Biopharmaceuticals (vaccines) have decided to partner again--now Nabi has granted GSK an option to exclusively license worldwide its Phase III smoking cessation candidate NicVAX as well as any variations on the vaccine's presentation, dosage, or administration. GSK has also received exclusive global rights to next-generation nicotine addiction vaccines (the companies are also calling these the "future candidates") incorporating both GSK's technology and Nabi's IP.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GSK options Nabi's nicotine addiction vaccine NicVAX; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice